Cargando…
MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1
Oxaliplatin is a commonly used chemotherapeutic drug for the treatment of advanced colorectal cancer. However, acquired drug resistance against oxaliplatin remains a major obstacle for efficient use of it, and mechanisms underlying oxaliplatin resistance are still required to be explored. In the pre...
Autores principales: | Liu, Hui, Cheng, Xin-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844747/ https://www.ncbi.nlm.nih.gov/pubmed/29552311 http://dx.doi.org/10.18632/oncotarget.24380 |
Ejemplares similares
-
Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b
por: Wang, Wei, et al.
Publicado: (2020) -
MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer
por: Qian, Xiao-Lan, et al.
Publicado: (2021) -
Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer
por: Ning, Tao, et al.
Publicado: (2021) -
Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia
por: Xu, Ling, et al.
Publicado: (2014) -
Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer
por: Liu, Tong, et al.
Publicado: (2019)